$300 Million Settlement Reached in Benicar Multi-District Litigation

Camden, NJ—August 02, 2017 — On August 1, 2017, a settlement of $300 million was reached with Daiichi Sankyo, a global pharmaceutical company selling olmesartan medoxomil, a popular prescription blood pressure medication marketed as Benicar®, Benicar HCT®, Azor®, and Tribenzor®.

More than 2,000 individuals have alleged severe and sometimes life-threatening gastrointestinal injuries as a result of ingesting the medications containing the active ingredient olmesartan medoxomil, which has been linked to sprue-like enteropathy and celiac disease-like symptoms that inhibit a person’s ability to absorb nutrients.

“We are very pleased with the outcome of this hard-fought litigation,” stated Christopher L. Coffin, co-lead counsel for the plaintiffs, per the Plaintiffs’ Negotiating Committee’s official news release. “This is a gratifying resolution for thousands of patients who suffered severe gastrointestinal injuries while using these blood pressure medications.”

The settlement was reached in the In Re: Benicar (Olmesartan) Products Liability Litigation, MDL No. 2606 pending in the U.S. District Court for the District of New Jersey, Camden division. The Honorable Robert Kugler appointed a Plaintiffs’ Negotiating Committee, which included Tara Sutton from Robins Kaplan LLP, partner and chair of Robins Kaplan’s Mass Tort Group

Robins Kaplan also had a pivotal role throughout the litigation. Upon consolidation of the MDL in 2015, Judge Kugler appointed Tara Sutton to the Plaintiffs’ Executive Committee and as chair of the Science Committee. Robins Kaplan Partner Gary Wilson was appointed to the Science Committee, Associate Holly Dolejsi was appointed to the Bellwether Selection Committee, and Associate Rayna Kessler served as the chair of the State/Federal Coordination for the Plaintiffs’ Steering Committee.

In addition to the federal litigation, Rayna Kessler was appointed liaison counsel in the multicounty litigation In Re: Benicar (Olmesartan Medoxomil) New Jersey Multicounty Litigation, Case No. 299, where dozens of cases were filed involving similar claims against Daiichi Sankyo.  Robins Kaplan actively litigated these cases for nearly three years.

Under the settlement, claimants who meet specified criteria will be eligible for payouts. Information regarding settlement eligibility criteria and deadlines for the Olmesartan Products Resolution Program may be found at